Evidence map›Paper›PMID 32624900›Full record

ArticleEngineering in life sciences2018

Biotechnological production of the angiotensin-converting enzyme inhibitory dipeptide isoleucine-tryptophan.

Lydia Michelke, Andreas Deussen, Karina Kettner, Peter Dieterich, Diana Hagemann, Thomas M Kriegel, Melanie Martin

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Engineering in life sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lydia MichelkeInstitute of Physiology Medical Faculty Carl Gustav Carus Technische Universität Dresden Germany.
Andreas DeussenInstitute of Physiology Medical Faculty Carl Gustav Carus Technische Universität Dresden Germany.
Karina KettnerInstitute of Physiological Chemistry Medical Faculty Carl Gustav Carus Technische Universität Dresden Germany.
Peter DieterichInstitute of Physiology Medical Faculty Carl Gustav Carus Technische Universität Dresden Germany.
Diana HagemannInstitute of Food Chemistry Technische Universität Dresden Germany.
Thomas M KriegelInstitute of Physiological Chemistry Medical Faculty Carl Gustav Carus Technische Universität Dresden Germany.
Melanie MartinInstitute of Physiology Medical Faculty Carl Gustav Carus Technische Universität Dresden Germany.
TU Dresden · DEUniversity Hospital Carl Gustav Carus · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptides with angiotensin-converting enzyme (ACE)-inhibitory and antihypertensive effects are suggested as innovative food additives to prevent or treat hypertension. Currently, these substances are isolated from food proteins following nonselective hydrolysis as a mixture of ACE-inhibitory peptides and other protein fragments. This study presents an innovative biotechnological method, based on recombinant DNA technology that was established to specifically produce the ACE-inhibitory dipeptide isoleucine-tryptophan. In a first step, a repetitive isoleucine-tryptophan construct fused to the maltose-binding protein was generated and expressed in

Indexed as

ACE‐inhibiting peptidesBioactive peptidesE. coliFunctional foodsRecombinant proteins

Identifiers

PMID32624900
PMCPMC6999327
OpenAlexW2778791431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.